Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Share News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 36.30
Bid: 36.30
Ask: 37.00
Change: 0.525 (1.45%)
Spread: 0.70 (1.928%)
Open: 35.80
High: 36.30
Low: 35.80
Prev. Close: 36.125
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Syntopix, Atlantic Coal, Brady...

Thu, 12th Nov 2009 14:32

Drug developer Syntopix shares rallied as it reported positive phase 2 results for its lead dermatological compound SYN0126, for the treatment of acneic skin. Following the results, Syntopix has decided to focus its development efforts around three specific core compounds: SYN0126, SYN1113 and SYN0017, in order to accelerate commercialisation. Syntopix has also renewed its exclusivity and evaluation agreement with another 'major consumer healthcare company' announced on 14 April 2009.The potential of the Stockton mine and introduction of a new mine plan have had the desired effect with the mine becoming cash flow positive from its operations, Atlantic Coal reports.Revenues of circa $4m were achieved from sales of 32,348 tons for the four months to October, compared to revenues of circa $3.4m from 27,223 tons sold during the 6 months to June 2009. The company has stock piles on site as at 31 October 2009 of 71,386 ROM tons and 6,365 tons of Clean Coal. This will be sold in the coming months and will have a positive impact on revenues going forward.Xstrata's copper arm in Chile has selected Brady's Aquarius solution to supply the organisation's metal trading business in that country.Recruiter Higham returned a profits £40,000 against a loss of £261,000 in the half year to September, despite revenue dipping to £3.77m (2008: £5.66m). The current business has been stabilised and there are signs of recovery showing in our niche areas, it added.Pharmaceutical Group Futura has announced a placing worth £1.46m to support the regulatory approval of its 'erectogenic' condom the CSD500, and to provide the company with additional working capital and funds for development projects.
More News
19 Sep 2018 11:40

Futura Medical Shares Down As Phase-Three Data Required For MED2002

LONDON (Alliance News) - Shares in Futura Medical PLC plunged on Wednesday after reporting that potential partners for the licensing of MED2002 have asked for further tests on the product before a

Read more
5 Sep 2018 16:13

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 6 September PPHE Hotel GroupHalf Year ResultsHunters PropertyHalf Year Year Year

Read more
18 Jun 2018 13:25

European Wealth Appoints Jonathan Freeman As Non-Executive Director

LONDON (Alliance News) - European Wealth Group Ltd said Monday it appointed Jonathan Freeman as non-executive director.Freeman currently holds the roles of non-executive chairman of LED of

Read more
13 Jun 2018 12:36

Futura Says Licensing Of Erectile Dysfunction Gel Remains Top Priority

LONDON (Alliance News) - Futura Medical PLC Chairman John Clarke said Wednesday the company continues to make "good progress" both in product development and commercialisation.In

Read more
26 Apr 2018 13:53

Futura Medical Begins Groundwork For MED 2002 Phase III Trial

LONDON (Alliance News) - Healthcare firm Futura Medical PLC said Thursday it has started preparing for a phase III trial for its proposed erectile dysfunction gel MED 2002.This trial what a

Read more
14 Mar 2018 16:08

Futura Medical Annual Loss Widens On Higher Research Costs

LONDON (Alliance News) - Futura Medical PLC said Wednesday that planned increase in research and development expenditure for the development of erectile dysfunction gel has in

Read more
10 Jan 2017 11:05

Futura Medical signs license agreement with Thornton & Ross

(ShareCast News) - Futura Medical, an AIM listed innovative healthcare company focused on transdermal technology, has signed a licensing agreement with Thornton & Ross for the commercialisation of TPR100, the company's novel diclofenac gel for pain relief. Thornton & Ross (T&R) is one of the largest

Read more
16 Nov 2016 09:28

Futura To Develop Two Dose Strengths Of Erectile Dysfunction Gel

Read more
27 Oct 2016 14:24

Futura Medical partner approved for erectogenic condom manufacture

(ShareCast News) - Advanced transdermal technology-focused healthcare company Futura Medical announced on Thursday that, as anticipated, its regulatory submission to allow TTK Protective Devices to manufacture its erectogenic condom, CSD500, has been approved by the relevant EU Notified Body with an

Read more
27 Oct 2016 08:11

Futura Medical To Raise Up To GBP12 Million To Speed Up Products (ALLISS)

Read more
7 Sep 2016 10:35

Futura Medical perks up on 'breakthrough' erectile dysfunction study

(ShareCast News) - Shares in AIM-listed Futura Medical perked up to a two-year high as the company revealed that trials of its erectile dysfunction (ED) treatment had found it to be effective, safe and with the potential to be the fastest-acting product on the market. A clinical study of Futura's ME

Read more
7 Sep 2016 07:25

LONDON BRIEFING: Change At Top For Well-Performing Hargreaves Lansdown

Read more
7 Sep 2016 07:11

Futura Medical Gets Positive Results On Erectile Dysfunction Gel

Read more
21 Jun 2016 07:11

Futura Medical Sees "Clear Potential For Value Generation This Year"

Read more
20 Jun 2016 07:26

Futura Medical Signs Southeast Europe Distribution Deal For Condom

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.